References

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Mifepristone and misoprostol (Mifegymiso) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May.

Cover of Clinical Review Report: Mifepristone and misoprostol (Mifegymiso)

Clinical Review Report: Mifepristone and misoprostol (Mifegymiso) [Internet].

Show details

Contents

< PrevNext >

References

1.: Costescu D, Guilbert E, Bemardin J, Black A, Dunn S, Fitzsimmons B, et al. Medical abortion. J Obstet Gynaecol Can. 2016 Apr;38(4):366-89. [PubMed: 27208607]
2.: Harwood B. First-trimester medication abortion (termination of pregnancy). In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2016 Aug 29 [cited 2016 Nov 24]. Available from: www.uptodate.com Subscription required.
3.: Induced abortions reported in Canada in 2014 [spreadsheet on the Internet], Ottawa (ON): CIHI; 2015 Dec. [cited 2016 Nov 24]. Available from: https://www.cihi.ca/sites/default/files/document/inducedabortioncan2014enweb.xlsx
4.: ^PrMifegymiso (Mifepristone tablet 200 mg Progesterone receptor modulator; and Misoprostol tablets 200 meg Prostaglandin) [product monograph], Toronto (ON): Celopharma Inc.; 2015 Jul 28.
5.: Pena M, Dzuba IG, Smith PS, Mendoza LJ, Bousieguez M, Martinez ML, et al. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City. Int J Gynaecol Obstet. 2014 Oct;127(l):82-5. [PubMed: 24957534]
6.: Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception. 2005 Nov;72(5):328-32. [PubMed: 16246656]
7.: Winikoff B, Dzuba IG, Creinin MD, Crowden WA, Goldberg AB, Gonzales J, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol. 2008 Dec;112(6):1303-10. [PubMed: 19037040]
8.: Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days’ gestation. Contraception. 2013 Apr;87(4):480-5. [PubMed: 23102797]
9.: Blum J, Raghavan S, Dabash R, Ngoc N, Chelli H, Hajri S, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012 Aug;118(2):166-71. [PubMed: 22682768]
10.: Ngoc NT, Blum J, Raghavan S, Nga NT, Dabash R, Diop A, et al. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception. 2011 May;83(5):410-7. [PubMed: 21477682]
11.: Say L, Kulier R, Gulmezoglu M, Campana A. Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev. 2005;(1). [PMC free article: PMC8406531] [PubMed: 15674900]
12.: ^PrMethotrexate: methotrexate tablets 2.5 mg (as methotrexate disodium), methotrexate injection 25 mg/mL (as methotrexate sodium) [product monograph]. Kirkland (QC): ^®T.M. Wyeth; 2016 Jul 18.
13.: Clinical Study Report: 302. A randomized study of buccal versus vaginal misoprostol administration 24 to 72 hours after mifepristone 200 mg for abortion up to 56 days gestation [CONFIDENTIAL internal manufacturer’s report], Rochester (NY): Strong Memorial Hospital; 2004 Feb 27.
14.: Clinical Study Report: 1.1.3. A randomized trial of buccal compared to oral misoprostol following mifepristone for medical abortion up to 63 days LMP [CONFIDENTIAL internal manufacturer’s report]. New York (NY): Gynuity Health Projects; 2007 Feb 28.
15.: Clinical Study Report: 1.1.4: Open-label, non-comparative, prospective multi-site study of mifepristone 200 mg followed 24-48 hours later by buccal misoprostol 800 meg for termination of pregnancy through 63 days’ gestation in Mexico City. [CONFIDENTIAL internal manufacturer’s report]. New York (NY): Gynuity Health Projects; 2011 Sep 20.
16.: Prescribing information: mifeprex (mifepristone) tablets, for oral use [label]. Silver Spring (MD): Food and Drug Administration; 2016 Mar.
17.: Safe abortion: technical and policy guidance for health systems [Internet]. 2nd. Geneva (CH): World Health Organization; 2012. [cited 2016 Nov 24]. Available from: http://apps.who.int/iris/bitstream/10665/70914/l/9789241548434eng.pdf?ua=1 [PubMed: 23700650]
18.: ^PrCytotec (misoprostol): 100, 200 meg tablets [product monograph]. Kirkland (QC): Pfizer Canada Inc.; 2003 Sep 11.
19.: CDR submission: Mifegymiso (Mifepristone tablet 200 mg Progesterone receptor modulator; and Misoprostol tablets 200 meg Prostaglandin) Company: Celopharma Inc. [CONFIDENTIAL manufacturer’s submission], Toronto (ON): Celopharma Inc; 2016 Feb.
20.: Health Canada reviewer’s report: Myfegymiso (Mifepristone and misoprostol) [CONFIDENTIAL internal report]. Ottawa: Therapeutics Products Directorate, Health Canada; 2013 Oct 7.
21.: Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review(s). In: Mifeprex (mifepristone) tablets. Company: Danco Labs. Application no.: 020687. Approval date: 09/28/2000 [Internet]. Rockville (MD): The Center; 2000 Jan 27 [cited 2016 Dec 22]. (FDA drug approval package). Available from: http://www.accessdata.fda.gov/drugsatfdadocs/nda/2000/20687MifepristonemedrP1.pdf
22.: Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Statistical review(s). In: Mifeprex (mifepristone) tablets. Company: Danco Labs. Application no.: 020687. Approval date: 09/28/2000 [Internet], Rockville (MD): The Center; 2000 Feb 14 [cited 2016 Dec 22], (FDA drug approval package). Available from: http://www.accessdata.fda.gov/drugsatfdadocs/nda/2000/20687Mifepristonestatr.pdf
23.: O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56. [PubMed: 497341]
24.: Paul M, Lichtenberg S, Borgatta L, Grimes DA, Stugglefield PG, Creinin MD, et al. Management of unintended and abnormal pregnancy: comprehensive abortion care. Hoboken (NJ): Wiley-Blackwell; 2009.
25.: Kulier R, Kapp N, Guimezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011;(11). [PMC free article: PMC7144729] [PubMed: 22071804]
26.: Abortion statistics, England and Wales: 2014; Summary information from the abortion notification forms returned to the Chief Medical Officers of England and Wales. [Internet]. London (GB): The Crown; 2015 Jun. [cited 2016 Dec 13]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachmentdata/file/433437/2014Commentarv5.pdf
27.: List of Mifepristone Approvals [Internet]. New York (NY): Gynuity Health Projects; 2015 Apr. [cited 2016 Dec 13). Available from: http://gvnuitv.org/resources/info/list-of-mifepristone-approvals/ Originally published in January 2004.
28.: Medical management of first-trimester abortion. Contraception. 2014 Mar [cited 2016 Dec 13];89(3): 148-61. [PubMed: 24795934]
29.: Dahiya K, Ahuja K, Dhingra A, Duhan N, Nanda S. Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion. Arch Gynecol Obstet. 2012 Apr;285(4):1055-8. [PubMed: 22009509]
30.: Chawdhary R, Rana A, Pradhan N. Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial. J Obstet Gynaecol Res. 2009 Feb;35(1):78-85. [PubMed: 19215552]
31.: Mittal S, Agarwal S, Kumar S, Batra A. Comparison or oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion. Indian J Med Res. 2005 Aug;122(2):132-6. [PubMed: 16177470]
32.: Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod [Internet]. 2003 Nov [cited 2016 Nov 16];18(11):2315-8. Available from: http://humrep.oxfordjournals.org/content/18/11/2315.full.pdf+html [PubMed: 14585880]
33.: Von HH, Honkanen H, Piaggio G, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. BJOG [Internet]. 2003 Sep [cited 2016 Nov 16];110(9):808-18. Available from: 10.1111/j.1471-0528.2003.02430.x/epdf [PubMed: 14511962] [CrossRef]
34.: Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR, Jr. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod [Internet]. 2002 Jun [cited 2016 Nov 16];17(6):1477-82. Available from: http://humrep.oxfordjournals.org/content/17/6/1477.full.pdf+html [PubMed: 12042265]
35.: Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001 Aug;64(2):81-5. [PubMed: 11704083]
36.: Health Canada Summary Basis of Decision: Myfegymiso (Mifepristone and misoprostol) [Internet]. Ottawa: Therapeutics Products Directorate, Health Canada; 2016 Aug 1. [cited 2016 Dec 19]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2016mifegymiso-160063-eng.php
37.: CFPC works on educational program covering newly approved Mifegymiso [Internet]. Mississauga (ON): The College of Family Physicians of Canada; 2015 Jul 31. [cited 2016 Dec 19]. Available from: http://www.cfpc.ca/July_31_2015_News_Release/
38.: Approved conditions of use for Mifepristone and Misoprostol (sold in Canada as Mifegymiso) [Internet]. Ottawa: Health Canada; 2016 Oct 13. [cited 2016 Dec 19]. Available from: http://www.hcsc.gc.ca/dhp--mps/prodpharma/activit/fs-fi/mifegymiso-cond-app-eng.php

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK534588

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Clinical Review Report: Mifepristone and misoprostol (Mifegymiso) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May. References.
PDF version of this title (1.9M)